The objective of this prospective study was to identify baseline angiogenic and inflammatory markers in serum as well as the baseline levels of immune cells in whole blood to predict progression free survival in patients with metastatic renal cell carcinoma treated with sunitinib. Blood samples were collected at baseline in all 90 patients to analyse serum angiogenic and inflammatory marker together with peripheral blood immunological marker. The association between each marker and sunitinib efficacy was analyzed. Univariate and multivariate Cox proportional model analyses were used to assess the correlation between those markers with survival. Baseline levels of interleukin-6, -8, high sensitivity C-reactive protein, and myeloid-derived suppressor cells were significantly higher in patients who progressed when compared with those with clinical benefit. Analysis by the Cox regression model showed that baseline interleukin-8, high sensitivity C-reactive protein and percentage of T helper type 1 cells were significantly associated with progression free survival in univariate analysis. Furthermore, in multivariate analysis, those three markers were independent indices to predict progression free survival. In conclusion, angiogenic (interleukin-8), inflammatory (interleukin-6, high sensitivity C-reactive), and immunologic (myeloid-derived suppressor cells, percentage of T helper type 1 cells) markers at baseline would predict response to sunitinib therapy and/or disease progression in patients with metastatic renal cell carcinoma.UMIN Clinical Trials Registry UMIN000009622 This article is protected by copyright. All rights reserved.
Cancer science. 2017 Jul 12 [Epub ahead of print]
Ryuichi Mizuno, Go Kimura, Satoshi Fukasawa, Takeshi Ueda, Tsunenori Kondo, Hidehiko Hara, Sunao Shoji, Kent Kanao, Hayakazu Nakazawa, Kazunari Tanabe, Shigeo Horie, Mototsugu Oya, Tokyo Metropolitan Study Group
Department of Urology, Keio University, school of medicine., Department of Urology, Nippon Medical School., Prostate Center and Division of Urology, Chiba Cancer Center., Department of Urology, Tokyo Women's Medical University., Department of Urology, Kyorin University School of Medicine., Department of Urology, Tokai University Hachioji Hospital., Department of Urology, Aichi Medical University., Department of Urology, Tokyo Women's Medical University Medical Center East., Department of Urology, Juntendo University Faculty of Medicine.